85 results on '"Interferon-β"'
Search Results
2. Toll-Like receptor 3-mediated interferon-β production is suppressed by oncostatin m and a broader epithelial-mesenchymal transition program
3. Cylindromatosis lysine 63 deubiquitinase (CYLD) suppress TLR3-mediated CCL5 expression in human renal proximal tubular epithelial cells
4. Mechanism of action and treatment of type I interferon in hepatocellular carcinoma
5. Nephrotic-range proteinuria and membranoproliferative glomerulonephritis-like pattern caused by interferon-β1b in a patient with multiple sclerosis
6. Benzyl-para-di-[5-methyl-4-(n-octylamino) pyrimidin-2(1H)one] as an interferon beta (IFN-β) modulator
7. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies
8. TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients
9. Combination chemoradiotherapy with temozolomide, vincristine, and interferon-β might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma
10. Cathepsin H deficiency decreases hypoxia-ischemia-induced hippocampal atrophy in neonatal mice through attenuated TLR3/IFN-β signaling
11. Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis
12. Prestimulation of Microglia Through TLR4 Pathway Promotes Interferon Beta Expression in a Rat Model of Alzheimer’s Disease
13. Decreased expression of miR-29 family associated with autoimmune myasthenia gravis
14. Interferon-β inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjögren’s syndrome
15. Long-term use of interferon-β in multiple sclerosis increases Vδ1−Vδ2−Vγ9− γδ T cells that are associated with a better outcome
16. The growth inhibitory effect of human gingiva-derived mesenchymal stromal cells expressing interferon-β on tongue squamous cell carcinoma cells and xenograft model
17. MEK inhibition drives anti-viral defence in RV but not RSV challenged human airway epithelial cells through AKT/p70S6K/4E-BP1 signalling
18. Interferon-β Inhibits Neurotrophin 3 Signalling and Pro-Survival Activity by Upregulating the Expression of Truncated TrkC-T1 Receptor
19. The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study
20. Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients
21. Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
22. Gcn5 and PCAF negatively regulate interferon‐β production through HAT‐independent inhibition of TBK1
23. Current Developments in Pharmacogenomics of Multiple Sclerosis
24. Interferon-β counter-regulates its own pro-apoptotic action by activating p38 MAPK signalling in human SH-SY5Y neuroblastoma cells
25. Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia
26. IFNβ‐dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage
27. Anticancer effects of the engineered stem cells transduced with therapeutic genes via a selective tumor tropism caused by vascular endothelial growth factor toward HeLa cervical cancer cells
28. Effect of Interferon-β on Neuroinflammation, Brain Injury and Neurological Outcome After Experimental Subarachnoid Hemorrhage
29. Disease-modifying drugs for multiple sclerosis and JC virus expression
30. Activation and regulation of interferon-β in immune responses
31. Interferon-β lipofection I. Increased efficacy of chemotherapeutic drugs on human tumor cells derived monolayers and spheroids
32. Interferon-β lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-β gene transfer to human tumor cells
33. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients
34. Kombinierter retinaler arteriovenöser Verschluss unter Interferon-β-Therapie
35. Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine
36. A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report
37. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition
38. Human neural stem cells transduced with IFN-β and cytosine deaminase genes intensify bystander effect in experimental glioma
39. Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines
40. Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-β
41. AAV-mediated Local Delivery of Interferon-β for the Treatment of Retinoblastoma in Preclinical Models
42. Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis model
43. Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKε‐mediated IRF activation
44. Interferon-b Inhibits Liver Metastases from Murine Colon 26 Carcinoma and its Highly Metastatic Variant
45. JC virus viremia in interferon-β-treated and untreated Italian multiple sclerosis patients and healthy controls
46. Inducible nitric oxide synthase activity is essential for inhibition of prostatic tumor growth by interferon-β gene therapy
47. Interferontherapie der Multiplen Sklerose: Synopsis der verschiedenen Applikationsformen
48. Interferon-β1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis
49. Thyroid autoimmunity and dysfunction associated with type I interferon therapy
50. Circulating CD4+CD25+ T Regulatory Cells Are Not Altered in Multiple Sclerosis and Unaffected by Disease-Modulating Drugs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.